According to the Complaint, Amarin Corporation plc is a biotechnology company with its headquarters located in Dublin, Ireland.

The Complaint alleges that during the Class Period, Defendants made false and misleading statements or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.

On May 14, 2019, the Court issued an Order appointing Co-Lead Plaintiffs and Counsel. Lead Plaintiffs filed an amended Complaint on July 22. Defendants filed a Motion to Dismiss the amended Complaint on October 4. On March 29, 2021, the Court issued an Order granting Defendants' Motion to Dismiss. Plaintiff was given leave to amend the Complaint.

Lead Plaintiffs filed a notice informing the Court of their intention to stand on their First Amended Complaint, and on April 30, 2021, the Court dismissed the case with prejudice. Lead Plaintiffs filed a notice appealing the Court's Dismissal Order on June 1. On June 14, 2022, the Court of Appeals affirmed the District Court's Dismissal Order.